• <tr id='eGK7rY'><strong id='eGK7rY'></strong><small id='eGK7rY'></small><button id='eGK7rY'></button><li id='eGK7rY'><noscript id='eGK7rY'><big id='eGK7rY'></big><dt id='eGK7rY'></dt></noscript></li></tr><ol id='eGK7rY'><option id='eGK7rY'><table id='eGK7rY'><blockquote id='eGK7rY'><tbody id='eGK7rY'></tbody></blockquote></table></option></ol><u id='eGK7rY'></u><kbd id='eGK7rY'><kbd id='eGK7rY'></kbd></kbd>

    <code id='eGK7rY'><strong id='eGK7rY'></strong></code>

    <fieldset id='eGK7rY'></fieldset>
          <span id='eGK7rY'></span>

              <ins id='eGK7rY'></ins>
              <acronym id='eGK7rY'><em id='eGK7rY'></em><td id='eGK7rY'><div id='eGK7rY'></div></td></acronym><address id='eGK7rY'><big id='eGK7rY'><big id='eGK7rY'></big><legend id='eGK7rY'></legend></big></address>

              <i id='eGK7rY'><div id='eGK7rY'><ins id='eGK7rY'></ins></div></i>
              <i id='eGK7rY'></i>
            1. <dl id='eGK7rY'></dl>
              1. <blockquote id='eGK7rY'><q id='eGK7rY'><noscript id='eGK7rY'></noscript><dt id='eGK7rY'></dt></q></blockquote><noframes id='eGK7rY'><i id='eGK7rY'></i>

                Exhibition Invitation | March 16-17 CIS-Asia 2023 12th Annual ChemPharma International Summit - Asia, you are invited to visit us at booth T85!



                Dear friends and partners,


                      Thank you for your full support and firm recognition! Linkchem will participate in the CIS-Asia 2023 12th Annual ChemPharma International Summit - Asia. We sincerely invite you to visit our booth to discuss about CMC innovative drug development and industry development.

                Date: March 16 - 17, 2023

                Location: International Convention Centre Hotel Society Hill Tianjin

                Organizers: Best Media, Chinese Pharmaceutical Association Pharmaceutical Engineering Professional Committee

                Booth No.: T85

                Meanwhile, you are also very welcome to attend our keynote speech at 9:30 a.m. on March 17, and panel discussion at 5:15 p.m. on March 16.

                Forum 2: Development of APIs for New Drugs

                Panel Discussion

                Topic: How to Select and Further Optimize API Processes during the Development of New Drugs?

                Date & Time: March 16 at 5:15 p.m.(Forum 2)

                Keynote Speech

                Topic: The Art of Small Molecule Drug Synthetic Route Design and Process Scale-up

                Date & Time: March 17 at 9:30 a.m.(Forum 2)

                Yongli Zhong


                Vice President and Chief Technology Officer(CTO)

                Dr. Zhong joined Linkchem in October 2022, and is the vice president and chief technology officer (CTO) of the company. He graduated from the Department of Chemistry, Sun Yat-sen University with a B.Sc. and a M.Sc. in organic chemistry, and taught for many years, during which he won two collective awards: Guangdong Province University Prize for Progress in Science, and Guangdong Province Second Prize Award in Natural Science. From 1995 to 1998, he obtained a Ph.D. in organic chemistry under the supervision of Professor Shing, Kung Ming Tony, Department of Chemistry, at the Chinese University of Hong Kong. In 1998, he was invited by Professor K. C. Nicolaou and completed Postdoc at UC San Diego, Scripps Research Institute until mid-2001. Dr. Zhong served at Merck's Research and Development Process in Rahway, New Jersey, USA since June 2001. He successively held the positions of Senior Scientist, Research Scientist and Principal Scientist, engaging in the design, research and development, optimization and commercialization of small molecule drug synthesis routes.

                In Merck’s 21-year process research and development career, Dr. Zhong was one of the key contributors to the design and development of commercial synthetic routes for 4 marketed drugs, Isentress, Grazoprevir, Relenactam and Vibegron, and led the design, development and production of a large number of API GMP routes for Merck’s drug candidates (all stages ranging from PCC to pre-commercial production). He has published over 90 scientific papers, 3 book chapters and filed 20 invention patents. Dr. Zhong has a strong industry background, outstanding innovation ability and rich experience in drug synthesis process design, development and management.


                In this conference, Linkchem will set up a special booth on site. You can communicate with our scientists and business team face to face. If you need to make an appointment, please email: We will contact you as soon as we receive your appointment information!

                       感谢您一直以来对凌凯医药的鼎力支持与坚定认可!凌凯医药将参加2023 CIS-Asia十二届化学制药国际峰会-亚洲,现诚挚邀请您∞莅临我司展位洽谈指导,共话CMC创新药开发与行业发展。


                展会地点:中国 · 天津社会山国际会议中心
                主办单位:百世传媒|Best Media、中国药学会制药工程专业委员会
                展 位 号:T85



                (论坛二会场ζ )







                钟永利于2022年10月加入凌凯医药,目前任公司副总裁兼首席技术官(CTO),本科和硕士研究生毕业于中山大学化学系有机专业,并留校◆任教多年,期间荣获◎集体奖两项:广东︾省高校科学技术进步一等奖和广东省自然科学二等奖。1995-1998年师从香港中文大学化学◤系成公明教授,攻读有机化学博士学位。1998年受美国加州圣地亚哥斯克里普斯研究所(The Scripps Research Institute) K. C. Nicolaou 教授邀请从事博士后研究直【到2001年中。从2001年6月始一直在美国新泽西↓州(New Jersey)拉威镇(Rahway)默沙东工艺研究与发展部(PR&D)任职,先后担任资深科学家、研究■员和首席科学家,从事小分子药物合成路线设计、研发、优化ㄨ和商业化开发。

                在默沙东21年工艺研发生涯♂里,钟博士是4个上市药Isentress 、Grazoprevir 、Relenactam 和Vibegron 商业化合成路线设计和研发ぷ的主要贡献者〗之一,主导@ 了默沙东大量候选药物API GMP 合成路线的设计、研发以及□生产(涵盖了从PCC 到各个阶段到准进入〇商业化生产)。累计发→表科学论文90多篇、3篇书章和申请发明专利▲20件。钟博士拥有深厚的行业背『景、杰出的创新能力和丰富的药物合成工艺设计研发和▓管理经验。